Oslo, Norway, March 21, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present ...

--IO Biotech, IO Biotech, ... today announced details of the invited oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’ s 37 th Annual Meeting.

IO Biotech is advancing in clinical trials its lead cancer vaccine candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates.

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ...

If anyone has information on the whereabouts of the TAK-279 poster, Fierce Biotech is standing by to collect tips. We intend to work tirelessly—at least until the next news cycle, anyway—to ...

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting Oct. 04, 2024 9:00 AM ET IO Biotech, Inc. (IOBT) ...

SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and ...

PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research. PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November ...

Oslo, Norway, March 21, 2017 PCI Biotech (PCIB.OL), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present a ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines ...